Who
Gary W. Pace
Director
Company insider
Files Form 4 as: Director, Cardiff Oncology; Director, Pacira BioSciences; Director, ResMed; Director, Imunon; Director, Peplin.
In numbers
- Trades disclosed
- 184
- Buys
- 25
- Sells
- 26
- Bought
- $5.8M
- Sold
- $32.7M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 7 Mar 2006
- Last trade
- 14 Jul 2026
- Last filed
- 16 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Jul 2026filed 16 Jul 2026 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $1000K687,285 at $1.46 | filing |
| 14 Jul 2026filed 16 Jul 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code P | —687,285 at $0.00 | filing |
| 14 Jul 2026filed 16 Jul 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code P | —687,285 at $0.00 | filing |
| 14 Jul 2026filed 16 Jul 2026 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $1.0M687,285 at $1.46 | filing |
| 18 Jun 2026filed 22 Jun 2026 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $37K30,000 at $1.22 | filing |
| 18 Jun 2026filed 22 Jun 2026 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $37K30,000 at $1.22 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 30 Jul 2025filed 31 Jul 2025 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $674K275,000 at $2.45 | filing |
| 30 Jul 2025filed 31 Jul 2025 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $37K15,000 at $2.45 | filing |
| 26 Jun 2025filed 27 Jun 2025 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,565 at $0.00 | filing |
| 11 Dec 2024filed 12 Dec 2024 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $910K350,115 at $2.60 | filing |
| 11 Dec 2024filed 12 Dec 2024 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $30K11,500 at $2.60 | filing |
| 27 Jun 2024filed 1 Jul 2024 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,700 at $0.00 | filing |
| 8 Mar 2024filed 8 Mar 2024 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $2.8M90,000 at $30.60 | filing |
| 7 Mar 2024filed 8 Mar 2024 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $871K28,257 at $30.81 | filing |
| 6 Mar 2024filed 8 Mar 2024 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $32K1,066 at $29.67 | filing |
| 19 Dec 2023filed 19 Dec 2023 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $41K30,000 at $1.37 | filing |
| 10 Nov 2023filed 14 Nov 2023 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $22K22,950 at $0.98 | filing |
| 15 Jun 2023filed 20 Jun 2023 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,700 at $0.00 | filing |
News
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic LeukemiaCRDF · manilatimes.net · 21 Oct 2026Analyzing Cardiff Oncology (NASDAQ:CRDF) and Xencor (NASDAQ:XNCR)CRDF · themarketsdaily.com · 21 Oct 2026Contrasting Nektar Therapeutics (NASDAQ:NKTR) and Cardiff Oncology (NASDAQ:CRDF)CRDF · tickerreport.com · 12 Oct 2026
0 headlines in the last 90 days name Gary W. Pace; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.